Dec. 17 at 1:17 PM
$SLS $SMMT $ABVX $CDTX 7 Full trading days left in EOY 2025. True longs here at Sellas about to witness one ☝️ of the most violent upticks in the history of The Wall Street in coming hours and days.
Sellas run up will be more violent than SMMT ABVX and CDTX due the fact that market opportunity of Sellas GPS and SLS009 combined with the ability of these 2 cancer platforms to tackle 40+ different cancer types that at peek sales will generate
$30 Billion plus annually for the Ultimate Big Pharmaceutical Suitor.
Last time a Biotechnology Co. that outshined Merck’s Keytruda was SMMT Therapeutics which went from little over
$2.00 low in 2024 to
$46.00 and market cap that exceeded
$26 Billion on phase 3 trial results based on a China 🇨🇳 only trial and I brought that up a year ago and the PPS has cut in over half since the peek.
Sellas GPS Regal is a Pivotal Registrational phase 3 study that is designed by FDA guidance of majority patients in USA 🇺🇸 and rest globally where success =
$120.00+✌️🙏
